Life-science briefing: Thursday, April 3, 2008
TODAY’S HEADLINES:
Mirna Thera spins out of Asuragen with $3M (release)
Stroke-therapy startup CoAxia raises $12M (release)
Stealthy device maker Synvascular gets $6.5M (peHUB)
AndroScience seeks $3.5M for anti-testosterone drugs (VentureWire)
Austria’s ProtAffin takes in €1.1M grant (release)
Singapore’s Moleac receives $3.5M for Chinese medicine (release)
Alethia Bio gets C$2.4M for antibody drugs (release)
Alba Thera names Bruce Peacock as CEO (release)
SkinMedica names Mary Fisher as CEO (release)
Mirna Thera spins out of Asuragen with $3M – Mirna Therapeutics, a newly minted Austin, Tex., startup focused… Continue Reading
Life sciences briefing: Monday, Dec. 10, 2007
TODAY’S HEADLINES:
Fundamental Applied Biology pulls in $21M for proteins without cells (release)
Diagnostics maker Asuragen receives $19M (release)
Stroke-device maker Neurovasx raises $8.5M (release)
Cancer-vaccine maker ImmunoVaccine Tech buys Immunotope, seeks $15M (release)
Vascular imager CardioSpectra sells itself to Volcano for $25M (release)
Spinal-implant maker Altiva sells to Exactech for $25M (release)
U.S. Healthworks acquires Inland Industrial in occcupational-healthcare consolidation (release)
Private-equity group acquires American Laser Centers (release)
Diagnostics maker Asuragen receives $19M — Asuragen, an Austin, Tex., developer of molecular diagnostics for… Continue Reading
Life sciences briefing: Wednesday, Oct. 24, 2007
Featured companies: Angstrom Medica, Asuragen, Aryx Therapeutics, HistoRx, MiMedx, Pioneer Surgical, Transfusion & Transplantation Technologies, Tolerx, Vivo Ventures
UPDATED: Expanded Aryx and XDx items.
UPDATE REDUX: Expanded Tolerx item, moved XDx to a separate post.
Aryx sets IPO range, seeks $92M for redesigned drugs — Fremont, Calif.-based Aryx Pharmaceuticals, a specialty pharma focused on producing safer versions of existing drugs, set its IPO range and now seeks to raise as much as $92 million. That’s a bit more than… Continue Reading